The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease
Open accessAbstract
Recent studies indicate that oxysterols, which are ligands for the nuclear hormone liver X receptors (LXR), decrease amyloid beta (Abeta) secretion in vitro. The effect was attributed primarily to the ATP-binding cassette transporter A1 (ABCA1) transcriptionally up-regulated by ligand-activated LXRs. We now examined the effect of the synthetic LXR ligand T0901317, which can be used in vivo, on Abeta production in vitro and in APP23 transgenic mice. T0901317 applied to a variety of in vitro models, including immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons caused a concentration-dependent decrease in Abeta secretion, and this effect was increased by the addition of apolipoprotein A-I. The inhibition of Abeta production by T0901317 was cell-type specific, being more prominent in primary neurons than in non-neuronal cells. Tangier fibroblasts lacking a functional ABCA1 secreted more Abeta than control fibroblasts, thus demonstrating the role of ABCA1 in amyloid precursor protein (APP) processing and Abeta generation. T0901317 treatment of 11-week-old APP23 mice for 6 days showed a significant increase in ABCA1 expression and a decrease in the ratio of soluble APP (sAPP)beta- to sAPPalpha-cleavage products. Most importantly, the treatment caused a statistically significant reduction in the levels of soluble Abeta40 and of Abeta42 in the brain these mice. Our experiments demonstrate that T0901317 decreases amyloidogenic processing of APP in vitro and in vivo, thus supporting the search for potent and specific LXR ligands with properties allowing therapeutic application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“dosing of APP transgenic mice with LXR agonists, which increase murine CNS apoE levels, also decrease A levels (Koldamova et al., 2005;Burns et al., 2006;Riddell et al., 2007).”
From Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels (2008) · cites this paper as Koldamova et al., 2005
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonist treatment alleviates AD-like pathology in mouse models of amyloidosis, possibly by inducing Abca1 expression (29, 43–48).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Koldamova et al. and Sun et al. reported that ABCA1 induction decreases Aβ levels in cells by inhibiting both β- and γ-cleavage of APP [62-64].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 gene ablation in mice decreased APOE lipidation and levels and increased Aβ accumulation in APP transgenic mouse models.”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonists have been shown to decrease A deposition in the brain while modestly increasing apoE expression (Koldamova et al., 2005;Zelcer et al., 2007;Fitz et al., 2010).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Koldamova et al., 2005
Experimental — accuracy not yet measured
In the citing paper
“Interestingly, several genes expressed in the liver including liver X receptors (LXRs) have been suggested as potential therapeutic targets for AD [189–191].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationRole of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics · doi:10.1038/11921 · Cited by 1,433
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J. C., Li, L., Lustig, K. D., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,303
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 282
Targeting liver X receptors in inflammation
Steffensen, K. R., Jakobsson, T., & Gustafsson, J.-Α. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.806490 · Cited by 65
Memory Deficits in APP23/ Abca1 +/− Mice Correlate with the Level of A β Oligomers
Lefterov, I. M., Fitz, N. F., Cronican, A. A., Lefterov, P., Staufenbiel, M., & Koldamova, R. P. (2009) · ASN NEURO · doi:10.1042/an20090015 · Cited by 63
Self-citationDiscovery and optimization of a novel series of liver X receptor-α agonists
Li, L., Liu, J., Zhu, L., Cutler, S., Hasegawa, H., Shan, B., & Medina, J. C. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.015 · Cited by 63
Dam, D. V., Vloeberghs, E., Abramowski, D., Staufenbiel, M., & Deyn, P. P. D. (2005) · CNS Spectrums · doi:10.1017/s1092852900010051 · Cited by 62
Self-citationCao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Hirsch-Reinshagen, V., & Wellington, C. L. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32813aeabf · Cited by 61
Liver X receptors: Emerging therapeutic targets for Alzheimer's disease
Sodhi, R. K., & Singh, N. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.008 · Cited by 61
Minh, T. N., Dodacki, A., Alata, W., Calon, F., Nicolic, S., Scherrmann, J., Farinotti, R., & Bourasset, F. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150350 · Cited by 65
Loane, D. J., Washington, P. M., Vardanian, L., Pocivavsek, A., Hoe, H.-S., Duff, K. E., Cernak, I., Rebeck, G. W., Faden, A. I., & Burns, M. P. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1595 · Cited by 57
Wu, M., Zhai, Y., Liang, X., Chen, W., Lin, R., Ma, L., Huang, Y., Zhao, D., Liang, Y., Zhao, W., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.842814 · Cited by 59
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease
Bossaerts, L., Cacace, R., & Broeckhoven, C. V. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00536-w · Cited by 56
Cui, W., Sun, Y., Wang, Z., Xu, C., Peng, Y., & Li, R. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.047 · Cited by 60
Kuntz, M., Candela, P., Saint-Pol, J., Lamartinière, Y., Boucau, M.-C., Sevin, E., Fenart, L., & Gosselet, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150469 · Cited by 55
Chuu, C., Chen, R.-Y., Hiipakka, R. A., Kokontis, J. M., Warner, K. V., Xiang, J., & Liao, S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.116 · Cited by 54
Panzenboeck, U., Kratzer, I., Sovic, A., Wintersperger, A., Bernhart, E. M., Hammer, A., Malle, E., & Sattler, W. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.01.013 · Cited by 57
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Wang, Y., Rogers, P. M., Stayrook, K. R., Chen, S., Varga, G., Shen, Q., Nagpal, S., & Burris, T. P. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048538 · Cited by 56
Liver X receptor modulators: a review of recently patented compounds (2007 – 2009)
Li, X., Yeh, V. S. C., & Molteni, V. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543771003621269 · Cited by 54
Screening for liver X receptor modulators: Where are we and for what use?
Buñay, J., Fouache, A., Trousson, A., de Joussineau, C., Bouchareb, E., Zhu, Z., Kocer, A., Morel, L., Baron, S., & Lobaccaro, J. A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15286 · Cited by 54
Liver X receptors, lipids and their reproductive secrets in the male
El-Hajjaji, F.-Z., Oumeddour, A., Pommier, A., Ouvrier, A., Viennois, É., Dufour, J., Caira, F., Drevet, J. R., Volle, D. H., Baron, S., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.004 · Cited by 58
Akanuma, S.-I., Ohtsuki, S., Doi, Y., Tachikawa, M., Ito, S., Hori, S., Asashima, T., Hashimoto, T., Yamada, K., Ueda, K., et al. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.12.002 · Cited by 50
Dietary oleic acid regulates hepatic lipogenesis through a liver X receptor-dependent signaling
Ducheix, S., Montagner, A., Polizzi, A., Lasserre, F., Régnier, M., Marmugi, A., Benhamed, F., Bertrand‐Michel, J., Mselli-Lakhal, L., Loiseau, N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181393 · Cited by 53
Fitz, N. F., Nam, K. N., Koldamova, R. P., & Lefterov, I. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14668 · Cited by 52
Self-citationChoi, J., Gao, J., Kim, J., Hong, C., Kim, J., & Tontonoz, P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1904 · Cited by 49
Role of Brain Liver X Receptor in Parkinson’s Disease: Hidden Treasure and Emerging Opportunities
Alnaaim, S. A., Al-Kuraishy, H. M., Alexiou, A. T., Papadakis, M., Saad, H. M., & Batiha, G. E. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03561-y · Cited by 52
microRNAs: A connection between cholesterol metabolism and neurodegeneration
Goedeke, L., & Fernandez-Hernando, C. F. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.034 · Cited by 49
Saint-Pol, J., Candela, P., Boucau, M.-C., Fenart, L., & Gosselet, F. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.008 · Cited by 50
Lamartinière, Y., Boucau, M.-C., Dehouck, L., Krohn, M., Pahnke, J., Candela, P., Gosselet, F., & Fenart, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170883 · Cited by 50
Jones, A., Kulozik, P., Ostertag, A., & Herzig, S. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0973 · Cited by 47
Status and future directions of clinical trials in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 49
Akanuma, S.-I., Hori, S., Ohtsuki, S., Fujiyoshi, M., & Terasaki, T. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.08.012 · Cited by 43
Oxysterol receptors and their therapeutic applications in cancer conditions
de Boussac, H., Alioui, A., Viennois, É., Dufour, J., Trousson, A., Vega, A., Guy, L., Volle, D. H., Lobaccaro, J. A., & Baron, S. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.820708 · Cited by 47
Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease
Adighibe, O., Arepalli, S., Duckworth, J., Hardy, J., & Vrièze, F. W. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.010 · Cited by 50
Liver X receptor modulators: a review of recently patented compounds (2009 – 2012)
Loren, J. C., Huang, Z., Laffitte, B. A., & Molteni, V. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.814640 · Cited by 45
Natural modulators of liver X receptors
Huang, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60013-3 · Cited by 44
The emerging roles of liver X receptors and their ligands in cancer
Lin, C.-Y., Vedin, L.-L., & Steffensen, K. (2016) · Expert opinion on therapeutic targets · doi:10.1517/14728222.2015.1081169 · Cited by 40
Pannu, P. S., Allahverdian, S., & Francis, G. A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.07.013 · Cited by 44
Gene–gene interaction between heme oxygenase-1 and liver X receptor-β and Alzheimer's disease risk
Infante, J., Rodríguez‐Rodríguez, E., Mateo, I., Llorca, J., Vázquez‐Higuera, J. L., Berciano, J., & Combarros, O. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.025 · Cited by 48
Mirza, Z., Kamal, M. A., buzenadah, A., Al-Qahtani, M., & Karim, S. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660154 · Cited by 42
The pleiotropic vasoprotective functions of high density lipoproteins (HDL)
Boyce, G. K., Button, E. B., Sonja, S. V., & Wellington, C. L. (2017) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160103 · Cited by 41
Paterniti, I., Campolo, M., Siracusa, R., Cordaro, M., Paola, R. D., Calabrese, V., Navarra, M., Cuzzocrea, S., & Esposito, E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174470 · Cited by 43
Association of ATP-Binding Cassette Transporter Variants With the Risk of Alzheimer‘s Disease
Cascorbi, I., Flüh, C., Remmler, C., Haenisch, S., Faltraco, F., Grumbt, M., Peters, M., Brenn, A., Thal, D. R., Warzok, R., et al. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.18 · Cited by 41
The Beneficial Role of Vitamin D in Alzheimer’s Disease
Lương, K. V. Q., & Nguyễn, L. (2011) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317511429321 · Cited by 40
Zerbinatti, C., Cordy, J. M., Chen, C.-D., Guillily, M. D., Suon, S., Ray, W. J., Seabrook, G. R., Abraham, C. R., & Wolozin, B. L. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-5 · Cited by 40
Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Atlante, A., Amadoro, G., Latina, V., & Valenti, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226742 · Cited by 40
Intracellular cholesterol homeostasis and amyloid precursor protein processing
Burns, M. P., & Rebeck, G. W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.004 · Cited by 39
Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease
Griffett, K., & Burris, T. P. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.036 · Cited by 42
Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma
Paterniti, I., Genovese, T., Mazzon, E., Crisafulli, C., Paola, R. D., Galuppo, M., Bramanti, P., & Cuzzocrea, S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06471.x · Cited by 39
Alzheimer's disease: Cholesterol a menace?
Mathew, A., Yoshida, Y., Maekawa, T., & Kumar, D. S. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.06.006 · Cited by 38
McCarty, M. F. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.067 · Cited by 37
Eckert, G. P., Vardanian, L., Rebeck, G. W., & Burns, M. P. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.05.063 · Cited by 39
RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment
Lefterov, I. M., Schug, J., Mounier, A., Nam, K. N., Fitz, N. F., & Koldamova, R. P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.019 · Cited by 36
Self-citationMinireview: Nuclear Receptor Regulation of Osteoclast and Bone Remodeling
Jin, Z., Li, X., & Wan, Y. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1316 · Cited by 38
Proton pump inhibitor Lansoprazole is a nuclear liver X receptor agonist
Cronican, A. A., Fitz, N. F., Pham, T., Fogg, A., Kifer, B., Koldamova, R. P., & Lefterov, I. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.018 · Cited by 36
Self-citationNam, K. N., Mounier, A., Fitz, N. F., Wolfe, C. M., Schug, J., Lefterov, I. M., & Koldamova, R. P. (2016) · Scientific Reports · doi:10.1038/srep24048 · Cited by 36
Self-citationYu, J., Ahn, S.-Y., Kim, H. J., Lee, M. Y., Ahn, S., Kim, J., Jin, S. H., Lee, E., Kim, G., Cheong, J. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00805 · Cited by 35
Guimaraes, M. E. N., Lopez-Blanco, R., Correa, J., Fernandez‐Villamarin, M., Millón, M. B. B., Adami, P. V. M., Morelli, L., Kumar, V., Wempe, M. F., Cuello, A. C., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c09159 · Cited by 36
Fitz, N. F., Castranio, E. L., Carter, A. Y., Kodali, R. B., Lefterov, I. M., & Koldamova, R. P. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132789 · Cited by 37
Self-citationOxysterols and the NeuroVascular Unit (NVU): A far true love with bright and dark sides
Saint‐Pol, J., & Gosselet, F. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.017 · Cited by 33
Protocol for fast screening of multi-target drug candidates: Application to Alzheimer’s disease
Thai, N. Q., Nguyen, H. L., Linh, H. Q., & Li, M. S. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.08.002 · Cited by 33
Báez-Becerra, C. T., Filipello, F., Sandoval-Hernández, A. G., Arboleda, H., & Arboleda, G. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9845-3 · Cited by 34
Regulation of α-synuclein expression by liver X receptor ligands in vitro
Cheng, D., Kim, W. S., & Garner, B. (2008) · Neuroreport · doi:10.1097/wnr.0b013e32831578b2 · Cited by 32
Cui, W., Sun, Y., Wang, Z., Xu, C., Xu, L., Wang, F., Chen, Z., Peng, Y., & Li, R. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0513-3 · Cited by 35
Schweinzer, C., Kober, A. C., Lang, I., Etschmaier, K., Scholler, M., Kresse, A. E., Sattler, W., & Panzenboeck, U. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110854 · Cited by 33
Hascalovici, J., Song, W., Vaya, J., Khatib, S., Fuhrman, B., Aviram, M., & Schipper, H. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05741.x · Cited by 29
Mapping ApoE/Aβ binding regions to guide inhibitor discovery
Liu, Q. R., Wu, W., Fang, C.-L., Li, R., Liu, P., Lei, P., Hu, J., Sun, X., Zheng, Y.-Z., Zhao, Y., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05019b · Cited by 29
Suon, S., Zhao, J. J., Villarreal, S. A., Anumula, N., Liu, M., Carangia, L. M., Renger, J. J., & Zerbinatti, C. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-44 · Cited by 31
Cholesterol and Synaptic Compensatory Mechanisms in Alzheimer's Disease Mice Brain During Aging
Jansen, D., Janssen, C. I. F., Vanmierlo, T., Dederen, P. J. W. C., van Rooij, D., Zinnhardt, B., Nobelen, C. L. M., Janssen, A.-L., Hafkemeijer, A., Mutsaers, M. P. C., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120298 · Cited by 29
Cholesterol independent effect of LXR agonist TO‐901317 on gamma‐secretase
Czech, C., Burns, M. P., Vardanian, L., Augustin, A., Jacobsen, H., Baumann, K., & Rebeck, G. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04467.x · Cited by 27
Activation of liver X receptor suppresses angiogenesis via induction of ApoD
Lai, C., Cheng, H., Lin, C., Huang, S., Chen, T., Chung, C., Chang, C., Wang, H., & Chuu, C. (2017) · The FASEB Journal · doi:10.1096/fj.201700374r · Cited by 29
Self-citationHerbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer’s disease
Kumar, A., Sharma, V., Singh, V. P., Kaundal, M., Gupta, M., Bariwal, J. B., & Deshmukh, R. R. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.05.009 · Cited by 29
Jan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.007 · Cited by 28
Pahnke, J., Bascuñana, P., Brackhan, M., Stefan, K., Namasivayam, V., Koldamova, R. P., Wu, J., Möhle, L., & Stefan, S. M. (2021) · Free Neuropathology · doi:10.17879/freeneuropathology-2021-3528 · Cited by 29
Self-citationChen, J., Zhao, L., Sun, D., Narsinh, K. H., Li, C., Zhang, Z., Qi, S., Wei, G., Li, W., Guo, W., et al. (2012) · Inflammation Research · doi:10.1007/s00011-012-0529-4 · Cited by 27
Inflammation at the blood-brain barrier: The role of liver X receptors
de Wit, N. M., Vanmol, J., Kamermans, A., Hendriks, J. J. A., & de Vries, H. E. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.09.015 · Cited by 27
Carter, A. Y., Letronne, F., Fitz, N. F., Mounier, A., Wolfe, C. M., Nam, K. N., Reeves, V. L., Kamboh, H., Lefterov, I., & Koldamova, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172161 · Cited by 28
Self-citationHu, Y., Yang, Y., Yu, Y., Wen, G., Shang, N., Zhuang, W., Lu, D., Zhou, B., Liang, B., Yue, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301913k · Cited by 24
Induction of Alzheimer’s-like changes in brain of mice expressing mutant APP fed excess methionine
McCampbell, A., Wessner, K., Marlatt, M. W., Wolffe, C., Toolan, D. M., Podtelezhnikov, A. A., Yeh, S., Zhang, R., Szczerba, P., Tanis, K. Q., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07087.x · Cited by 24
MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease
Yoon, H., Flores, L. F., & Kim, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.04.020 · Cited by 23
Marín, F. R., Soler‐Rivas, C., Martín‐Hernández, R., & Rodríguez‐Casado, A. (2014) · Cholesterol · doi:10.1155/2014/639751 · Cited by 25
Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?
Akram, A. M., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. H. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-36 · Cited by 25
Regulated Proteolysis of APP and ApoE Receptors
Hoe, H., & Rebeck, G. W. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8017-0 · Cited by 23
High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease
Pedrini, S., Chatterjee, P., Hone, E., & Martins, R. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15170 · Cited by 22
Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice
Cohen, A. D., Ikonomović, M. D., Abrahamson, E. E., Paljug, W. R., DeKosky, S. T., Lefterov, I. M., Koldamova, R. P., Shao, L., Debnath, M., Mason, N. S., et al. (2009) · Letters in Drug Design & Discovery · doi:10.2174/157018009789057526 · Cited by 22
Self-citationFan, J., Stukas, S., Wong, C., Chan, J., May, S., DeValle, N., Hirsch-Reinshagen, V., Wilkinson, A., Oda, M. N., & Wellington, C. L. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014365 · Cited by 21
Theofilopoulos, S., & Arenas, E. (2015) · F1000Prime Reports · doi:10.12703/p7-37 · Cited by 22
Martens, N., Zhan, N., Voortman, G. J., Leijten, F. P. J., van Rheenen, C., van Leerdam, S., Geng, X., Huybrechts, M., Liu, H., Jonker, J. W., et al. (2023) · Nutrients · doi:10.3390/nu15133004 · Cited by 23
Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets
Wang, N.-Q., Sun, P.-X., Shen, Q.-Q., & Deng, M.-Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04672-w · Cited by 19
Hormonal modulators of glial ABCA1 and apoE levels
Fan, J., Shimizu, Y., Chan, J. Y., Wilkinson, A., Ito, A., Tontonoz, P., Dullaghan, E. M., Galea, L. A. M., Pfeifer, T. A., & Wellington, C. L. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m042473 · Cited by 20
A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson’s disease
Fu, Y., Pickford, R., Galper, J., Phan, K., Wu, P., Li, H., Kim, Y., Dzamko, N. L., Halliday, G. M., & Kim, W. S. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00632-2 · Cited by 19
Fessler, M. B. (2008) · Current Signal Transduction Therapy · doi:10.2174/157436208784223170 · Cited by 19
Davis, W. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908900 · Cited by 18
Wu, B., Liu, Y., Li, H., Zhu, L., Zeng, L., Zhang, Z., & Peng, W. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391305 · Cited by 22
Jasmin, S. B., Pearson, V., Lalonde, D., Domenger, D., Théroux, L., & Poirier, J. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.016 · Cited by 19
Vidal, V., Puente, A., García-Cerro, S., García‐Unzueta, M. T., Rueda, N., Riancho, J., & Martínez‐Cué, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.613211 · Cited by 16
Lu, R., Ito, J., Iwamoto, N., Nishimaki‐Mogami, T., & Yokoyama, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800594-jlr200 · Cited by 16
Dai, B., Lei, C., Lin, R., Tao, L., Yue, B., Peng, H., & Lei, B. (2017) · Inflammation Research · doi:10.1007/s00011-017-1036-4 · Cited by 15
Sun, Y., Fan, J. K., Zhu, Z., Guo, X., Zhou, T., Duan, W., & Shen, X. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.050 · Cited by 15
Brain cholesterol in normal and pathological aging
Vanmierlo, T., Lütjohann, D., & Mulder, M. T. (2011) · Oléagineux Corps gras Lipides · doi:10.1051/ocl.2011.0398 · Cited by 15
Ishida, E., Hashimoto, K., Okada, S., Satoh, T., Yamada, M., & Mori, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.023 · Cited by 15
Metadata
- Authors
- Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S.
- Affiliations
- University of Pittsburgh (US)
- Novartis Institutes for BioMedical Research (CH)
- University of Münster (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Koldamova, Radosveta P.
- Lefterov, Iliya M.
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 6
- Pages
- 4079-4088
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1996457468
- Cited by
- 279
- References
- 55
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 17 · 2013: 22 · 2012: 15
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health
- National Institute on Aging (AG 18558, AG 23304, R03AG023304)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- liver X receptor, T0901317, amyloid-beta, Alzheimer's disease, ABCA1, oxysterols, APP processing, APP23 transgenic mice, apolipoprotein A-I, soluble APP alpha, cell type specificity, LXR ligands
- MeSH terms
- Liver X Receptors, Benzenesulfonamides, Alzheimer Disease, Animals, Anticholesteremic Agents, Brain, Cloning, Molecular, Disease Models, Animal, DNA-Binding Proteins, Enzyme-Linked Immunosorbent Assay, Fibroblasts, Fluorocarbons, Humans, Hydrocarbons, Fluorinated, Ligands, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Protein Binding, Sulfonamides, Time Factors, Transcription, Genetic, Transfection, Blotting, Western, Up-Regulation, Amyloid beta-Protein Precursor, Apolipoprotein A-I, DNA, Complementary, Simplexvirus, Receptors, Cytoplasmic and Nuclear, Immunoprecipitation, Mice, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
